The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.
 
Gottfried E. Konecny
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Merck
Research Funding - Lilly (Inst); Merck (Inst)
Expert Testimony - Foundation Medicine
(OPTIONAL) Uncompensated Relationships - Repare Therapeutics
 
Andrea Elisabeth Wahner Hendrickson
Consulting or Advisory Role - Oxcia
Speakers' Bureau - OncLive
Research Funding - Amgen (Inst); ProLynx (Inst)
Patents, Royalties, Other Intellectual Property - TORL Therapeutics (Inst)
 
Boris Winterhoff
Stock and Other Ownership Interests - Exact Sciences; Verastem
 
Cinthiya Chander
No Relationships to Disclose
 
Sanela Bilic
Consulting or Advisory Role - Bicara Therapeutics (Inst)
 
Simon Davenport
No Relationships to Disclose
 
Adrine Chung
Employment - 1200 Pharma; TORL Biotherapeutics
Travel, Accommodations, Expenses - TORL Biotherapeutics
 
Lei-Lani Miller
No Relationships to Disclose
 
Michael F. Press
Stock and Other Ownership Interests - Torl Biotherapeutics
Consulting or Advisory Role - AstraZeneca; Biocartis; Cepheid; Lilly; Lilly; Merck; Novartis; Zymeworks
 
Stephen P. Letrent
Employment - TORL Biotherapeutics
Leadership - Torl Biotherapeutics
Stock and Other Ownership Interests - Torl Biotherapeutics
 
Dennis J. Slamon
Leadership - 1200 Pharma; Biomarin; Torl Biotherapeutics
Stock and Other Ownership Interests - Amgen; Amgen; BioMarin; Merck Sharp & Dohme; Pfizer; Seagen; Vertex
Honoraria - Novartis
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Seagen
Research Funding - Novartis; Pfizer
Travel, Accommodations, Expenses - Biomarin; Novartis; Pfizer